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Alzheimer’s disease (AD) is the most common neurode-
generative disorder of the aging population; usually affecting
people over the age of 65 years and resulting in progressive
cognitive and functional decline. DetectingAD at the earliest
possible stage is vital to enable trials of disease modification
agents and considerable efforts are being invested in the iden-
tification and replication of biomarkers for this purpose.
Such biomarkers currently include measures of tau and
amyloid beta (Ab) in cerebrospinal fluid (CSF), brain atro-
phy using magnetic resonance imaging (MRI), and measures
of Ab pathological load using positron emission tomography
(PET). All these approaches are promising, although molec-
ular imaging is currently a costly procedure available in rela-
tively few centers and lumbar puncture is moderately
invasive. Furthermore, repeated measures are problematical
in both cases.
Blood (plasma) on the other hand is amore accessible bio-
fluid suitable for repeated sampling. This led many groups
including ours to investigate the potential of a diagnostic
signal in blood. Using a case-control study design with a
gel-based approach (two-dimensional gel electrophoresis
and liquid chromatography tandem mass spectrometry)
two proteins (complement factor H [CFH] and alpha-
2-macroglobulin [A2M]) were observed as potential markers
of AD [1], both of which were subsequently replicated by
independent groups [2,3]. In the same study we observed
changes in serum amyloid P (SAP), complement C4 (CC4),
and ceruloplasmin, all of which have been implicated in
AD pathogenesis [4–6]. However, case-control studies are
problematical when there is a long prodromal disease phase.
In such instances a large proportion of apparently normal
controls already harbors the disease processes and hence
may already have a peripheral biomarker disease signature.
To overcome the limitations of case-control design, we
searched for proteins associated with surrogates of disease
severity (hippocampal atrophy and clinical progression),
and identified Clusterin as a marker associated with both
these surrogate measures [7]. Building on this “endopheno-
type” discovery approach we subsequently found transthyre-
tin (TTR) and apolipoprotein A1 (ApoA1) to be associated
with faster declining AD subjects and increased plasma
apolipoprotein E (ApoE) levels related to increased Ab
burden in the brain [8,9].
These studies, and those from other groups, have identi-
fied a set of proteins that might act as biomarkers relevant
to AD. However such findings require replication, in large
studies, ideally using samples drawn from more than one
cohort source and using a platform that enables multiplex-
ing. We therefore developed multiplex panels using our dis-
covery proteins together with additional putative candidate
biomarkers that have been implicated in AD and neurode-
generation (Supplementary Table S1).
The aims of the current study were (1) to validate a set of
blood-based biomarkers in a large multicenter cohort withspecified a priori outcomevariables of the disease endopheno-
type measure of atrophy on MRI and of clinical severity and
(2) to determine the accuracy of amultiplexed panel of disease
relevant biomarkers in predicting conversion ofmild cognitive
impairment (MCI) to dementia in a defined time period.2. Methods
2.1. Subjects and clinical classification
Plasma samples from AD, MCI subjects and elderly non-
demented controls were selected from three independent
studies. AddNeuroMed (ANM) a multicenter European
study [10], Kings Health Partners-Dementia Case Register
(KHP-DCR) a UK clinic and population based study and
Genetics AD Association (GenADA) a multisite case-
control longitudinal study based in Canada [11]. The diag-
nosis of probable AD was made according to Diagnostic
and Statistical Manual for Mental Diagnosis, fourth edition
and National Institute of Neurological, Communicative Dis-
orders and Stroke–Alzheimer’s disease and Related Disor-
ders Association criteria. MCI was defined according to
Petersen criteria [12]. Standardized clinical assessment
included the Mini-Mental State Examination (MMSE) for
cognition and for global levels of severity the Clinical
Dementia Rating (ANM and KHP-DCR only). The human
biological samples were sourced ethically and their research
use was in accord with the terms of the informed consents.
In total we examined plasma samples from 1148 subjects:
476 with AD, 220 with MCI, and 452 elderly controls with
no dementia (Table 1). The APOE single nucleotide poly-
morphisms (SNPs) rs429358 and rs7412 were genotyped
using Taqman SNP genotyping assays (determined by allelic
discrimination assays based on fluorogenic 50 nuclease activ-
ity) and the allele inferred.
2.2. Cognitive decline
Cognitive decline, as determined by the slope of change
in cognition, was calculated for a subset of AD subjects
(n5 342) who had a minimum of three separate MMSE as-
sessments. The rate of cognitive declinewas calculated sepa-
rately for ANM because it had a different following up
interval (every 3 months for 1 year) in comparison to DCR
and GenADA, which were followed up yearly for a period
of at least 3 years. Linear mixed effect models were gener-
ated using the package “nlme” in R. We estimated the rate
of change using a multilevel linear model with random inter-
cepts and random slopes adjusted for subject and center level
clustering. Covariates including age at baseline, gender,
APOE ε4 allele presence, and years of education were inves-
tigated for their effect on the rate of decline. Age at baseline
and years of education had a significant effect on the rate
(P value , .05) and thus were included as fixed effects in
the final model. The slope coefficient obtained from the final
model for each sample was then used as a rate of cognitive
change, defined as the change in MMSE score per year.
Table 1
Subject demographics
Control
MCI
AD SignificanceMCInc MCIc
N 452 169 51 476
Age (yrs) 75.6 (66.3, 53–93) 76.3 (65.7, 65–90) 76.2 (66.9, 56–89) 77.0 (66.4, 58-96) P 5 .012y
Sex (%, female) 55.6% 50.1% 49.1% 49.4% P 5 .277
APOE genotype (%, e41) 28% 35% 55% 59% P , .001y
MMSE 29.0 (61.2, 22–30) 26.9 (62.9, 0–30) 26.3 (62.1, 18-30) 20.8 (65.4, 0–30) P , .001*
CDR (sum of boxes) 0.18 (60.4, 0–3) 1.82 (60.9, 0–4.5) 2$41 (60.9, 0.5–5) 4.04 (63.2, 0–20) P , .001*
Abbreviations: MCI, mild cognitive impairment; MCInc, mild cognitive impairment non-converter; MCIc, mild cognitive impairment converter; AD,
Alzheimer’s disease; APOE, apolipoprotein E; MMSE, Mini-Mental State Examination; CDR, clinical dementia rating; mean (6standard deviation, range),
analysis of variance was performed and if significant a Tukey’s post hoc comparison was carried out.
*Significance across all three groups.
yControl compared with AD.
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High-resolution sagittal 3D T1-weighted Magnetization
prepared rapid gradient-echo (MPRAGE) volume (voxel
size 1.1 ! 1.1 ! 1.2 mm3) and axial proton density/
T2-weighted fast spin echo images were acquired on 1.5 T
MRI scanners for 476 of the subjects (179 control, 123 MCI,
and 174 AD) as previously reported [13]. The MPRAGE vol-
ume was acquired using a custom pulse sequence specifically
designed for the Alzheimer’s DiseaseNeuroimaging Initiative
(ADNI) study to ensure compatibility across scanners [14].
Full brain and skull coveragewere required for allMR images
according to previously published quality control criteria
[13,15]. Image analysis was carried out using the FreeSurfer
image analysis pipeline (version 5.1.0) to produce regional
cortical thickness and subcortical volumetric measures as
previously described [16,17]. This segmentation approach
has been previously used for analysis in imaging proteomic
studies [18] and AD biomarker discovery [16]. All volumetric
measures from each subject were normalized by the subject’s
intracranial volume,whereas cortical thicknessmeasureswere
used in their raw form [19].Measures of hippocampal volume,
entorhinal cortex volume, and ventricular volumewere chosen
as MRI endophenotypes of AD. For the evaluation of hippo-
campal atrophy the MRI data were stratified into high and
low atrophy for the MCI group based on their median volu-
metric measures.2.4. Immunoassay–Luminex measurement
All candidate proteins were measured using multiplex
bead assays (Luminex xMAP) (Supplementary S1) incorpo-
rated in 7 MILLIPLEXMAP panels (Supplementary S2 and
S3) run on the Luminex 200 instrument according to manu-
facturer’s instructions.2.5. Data preprocessing
Before statistical analysis, we examined the performance
of each assay using quality checks (QC) as outlined in
the Supplementary Material. Median fluorescent intensity(MFI) was measured using xPONENT 3.1 (Luminex Corpo-
ration) and exported into Sigma plot (Systat Software;
version 12) for estimation of protein concentrations using
a five-parameter logistic fit. Briefly, all analytes that passed
QC checks based on the following four criteria (standard
curve linearity, intra-assay coefficient of variation [CV],
interassay coefficient of variation for reference sample,
and percentage of missing data; Supplementary Material
S4) were taken forward for further analysis.2.6. Statistical analysis
2.6.1. Univariate analysis
Univariate statistical analysis was performed in SPSS 20
(IBM). All raw MFI measures were log10 transformed to
achieve normal distribution. Covariates including age, gender,
plasma storage duration (days), and center were investigated.
We found that most proteins were significantly affected by
these covariates and therefore values were adjusted using a
generalized linear regression model (GLM). All subsequent
analysis was performed on theGLMadjusted data. Partial cor-
relation (adjusting for APOE genotype) analysis was per-
formed to examine associations with either structural MRI
brain imaging or cognition assessments. Correlations were
performed separately within diagnostic groups due to the
discrete nature of the clinical scores across all groups. The pro-
teinswere also analyzed individually for their associationwith
disease phenotypes: disease status (AD vs. control) via anal-
ysis of covariance (adjusting for APOE genotype). Multiple
linear regressions were performed to test how combinations
of proteins could predict hippocampal volume.
2.6.2. Classification analysis
Class prediction and attribute selection were performed
using WEKA (University of Waikato). Naive Bayes Simple
algorithm was used with default settings unless stated
otherwise. The data set was randomly split into 75%
train and 25% test for the MCI-converter (MCIc) and
MCI-nonconverter (MCInc) groups. Attribute selection
was performed using the Classifier Subset Evaluator with
Table 2
Proteins identified as significantly associated with structural brain MRI measures in the (A) MCI group and (B) AD group
(A) MCI group
MRI brain region Protein Correlation coefficient* Significance (two-tailed) df
Ventricular volume Clusterin 0.23 0.01 115
RANTES 20.19 0.03 116
Mean hippocampal volume Clusterin 20.38 0.00 115
NSE 0.22 0.02 116
Right Entorhinal thickness Clusterin 20.22 0.02 115
Left Entorhinal thickness Prealbumin 20.20 0.04 109
Mean Entorhinal volume n/a n/a n/a n/a
Mean Entorhinal Thickness n/a n/a n/a n/a
Whole Brain Volume Clusterin 20.25 0.01 118
NSE 0.21 0.02 119
RANTES 0.19 0.04 119
(B) AD group
MRI brain region Protein Correlation coefficient* Significance (2-tailed) df
Ventricular volume A1AT 0.24 0.01 119
NSE 0.16 0.03 169
Mean hippocampal volume BDNF 20.21 0.02 123
ApoC3 20.18 0.02 168
ApoA1 20.15 0.04 169
ApoE 20.15 0.05 169
Right entorhinal thickness n/a n/a n/a n/a
Left entorhinal thickness n/a n/a n/a n/a
Mean entorhinal volume ApoC3 20.20 0.01 168
ApoE 20.18 0.02 169
Mean entorhinal thickness ApoC3 20.22 0.01 168
ApoA1 20.21 0.01 169
ApoE 20.2 0.01 169
Prealbumin 20.15 0.05 158
Whole-brain volume ApoE 20.19 0.02 145
ApoA1 20.19 0.02 145
AB40 0.17 0.04 141
Abbreviations: MRI, magnetic resonance imaging; MCI, mild cognitive impairment; AD, Alzheimer’s disease; NSE, neuron-specific enolase; RANTES,
Regulated on Activation, Normal T Cell Expressed and Secreted; n/a, no significant association observed.
*Pearson’s correlation coefficient.
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tions of attribute selection were performed ranked by times
observed. Proteins seen greater than three or more times
were taken forward as predictor variables (Table 3). Any
class imbalance was overcome by applying the Synthetic
Minority Oversampling Technique in WEKA.
2.6.3. Cut-off point analysis
Untransformed protein concentrations on the full data set
(n 5 169, MCIc, and n 5 51, MCInc) were binarised at
different cut-off points using the upper and lower quartile
ranges and the percentile rank. A minimum of three cut-off
concentrations were tested per protein. Logistic regression
analysis was performed on individual cut-off concentrations
and selected based on their accuracy of predicting conversion.
3. Results
3.1. Study participants
The demographic and clinical characteristics of partici-
pants from the three cohorts are presented in Table 1. TheAD group were marginally, but significantly older than con-
trols (AD: mean 77 years, controls: 75 years, P 5 .01). The
frequency of the APOEε4 allele was higher in MCI and AD
groups than in controls.3.2. Plasma proteins and brain atrophy
Of the 26 proteins measured only two proteins were
found to be significantly different between AD and controls
(ApoE: F 5 6.5, P , .001; CFH: F 5 6.1, P , .001). How-
ever, using partial correlation, and adjusting for APOE, we
identified a number of plasma proteins that were signifi-
cantly associated with atrophy using MRI measures of one
or more of the brain regions; hippocampus, entorhinal cor-
tex, ventricles, and whole-brain volume in the disease groups
(Table 2A and B). Controlling for multiple testing, only
Clusterin (MCI group: P , .001) and ApoE (AD group:
P 5 .0014) remained significant.
We then set out to identify proteins that collectively
would predict disease progression, as represented by the sur-
rogate of hippocampal atrophy, in a predisease group of
Table 3
Proteins observed in the feature selection
Protein
No. of times
observed in
feature selection Protein
No. of times
observed in
feature selection
Transthyretin 5 CathepsinD 1
Clusterin 4 ApoE 1
Cystatin C 4 SAP 0
A1AcidG 4 Ceruloplasmin 0
ICAM1 4 NCAM 0
CC4 4 NSE 0
PEDF 4 VCAM1 0
A1AT 4 A2M 0
APOE genotype 3 B2M 0
RANTES 3 BDNF 0
ApoC3 3 CFH 0
PAI-1 2 ApoA1 0
CRP 2 Ab40 0
Abbreviations: NSE, neuron-specific enolase; SAP, serum amyloid P;
CFH, complement factor H; CRP, C-reactive protein.
NOTE. Ranked according to the number of times a protein was observed
in the feature selection. Proteins highlighted in bold were taken forward as
the predictors for MCI conversion.
Fig. 1. Feature selection workflow used to select the best attributes for mild
cognitive impairment converter (MCIc) classification.
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fied six proteins (Clusterin, regulated on cctivation, normal
T cell expressed and secreted [RANTES], neuron-specific
enolase [NSE], TTR, vascular cell adhesion molecule 1
[VCAM-1], and SAP) that predicted 19.5% (P 5 .006) of
hippocampal volume in subjects with MCI. We observed a
different combination of proteins associated with atrophy
in the AD group. Using linear regression analysis, seven pro-
teins (APOA1, alpha-1 antitrypsin [A1AT], ApoC3, brain-
derived neurotrophic factor [BDNF], AB40, plasminogen
activator inhibitor-1 [PAI-1], and NSE) in the AD group
were able to predict 11.9% (P 5 .039) of hippocampal
volume.
In summary we found an association of Clusterin with
greater atrophy, and a trend toward reduced RANTES,
NSE, and TTR levels in the MCI group. In the AD group
A1AT, NSE, ApoC3, ApoA1, ApoE, and BDNF plasma
levels were increased in subjects with increased atrophy.
3.3. Plasma proteins clinical cognition and cognitive
decline
We examined the relationship between these proteins and
disease severity as measured by cognition at the time of sam-
pling and by the rate of change in cognition. In the MCI
group at the point of sampling, both ApoE and C-reactive
protein (CRP) negatively correlated with MMSE (ApoE:
r 5 20.15, P 5 .001; CRP: r 5 20.186, P 5 .007).
In the AD group at the point of sampling ApoE, CFH,
neural cell adhesion molecule [NCAM], AB40, A1AcidG,
and Clusterin were all negatively correlated with MMSE
(ApoE: r 5 20.150, P 5 .001; CFH: r 5 20.104,
P 5 .026; NCAM: r 5 20.114, P 5 .014; AB40:r 5 20.161, P 5 .001; A1AcidG: r 5 20.135, P 5 .004;
Clusterin: r 5 20.135, P 5 .004).
Furthermore, we assessed the association of the proteins
with longitudinal prospective MMSE change in the AD
group. Three proteins, NCAM, soluble receptor for
advanced glycation end products [sRAGE], and intercellular
adhesion molecule [ICAM], were significantly associated
with the rate of change in cognition; NCAM and sRAGE
were both negatively correlated (NCAM: r 5 20.129,
P 5 .0018; sRAGE: r 5 20.125, P 5 .029), whereas
ICAM was positively correlated (ICAM: r 5 0.108,
P 5 .047).3.4. Protein biomarkers to predict disease conversion:
MCI to AD
In summary we confirm that a number of proteins, previ-
ously identified as putative markers of AD, correlated with
disease severity, measured by MRI or severity of cognitive
impairment not only in disease but in the predisease state
of MCI. We therefore reason that if these proteins are reflect-
ing pathological load, theymay also be markers predictive of
conversion from predisease states such as MCI to clinical
dementia.
To test this, we used a machine learning approach (Naive
Bayes Simple) with feature selection on a training data set
(Figure 1) and then applied this to a test set. The average
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(375 days, SD5 23 days). Ten proteins (TTR, Clusterin, cys-
tatin C, A1AcidG, ICAM1, CC4, pigment epithelium-derived
factor [PEDF], A1AT, RANTES, ApoC3) plus APOE geno-
type had the greatest predictive power (Table 3). The receiver
operating curve characteristic (ROC) for the independent test
set is shown in Figure 2A. The ROC area under the curve
(Table 4A) of the test set was 0.78 (protein only) and 0.84
(protein1 APOE genotype). To test the accuracy, we investi-
gated three different sensitivity cut-off points at 30%, 50%,
and 85%. The optimal accuracy was observed at the 85%
sensitivity with the test achieving an accuracy of 87% with a
specificity of 88%.
We then investigated whether combining structural
MRI data with these 10 proteins observed in the MCI
conversion data would improve classification accuracy.
MRI brain measures for a subset of subjects were com-
bined with the protein data and the Naive Bayes algorithm
was applied. In this smaller data set the proteins alone
performed very well when tested at the three different
sensitivity cut-offs (cut-off: accuracy; 30%: 83.3%, 50%:
80.6%, 85%: 69.4%). The addition of MRI data only
marginally improved the accuracy at two cut-off points
(cut-off: accuracy 30%: 86%; 50%: 83%) but reduced it
at the 85% sensitivity cut-off to 64% (Figure 2B and
Table 4B).3.5. Concentration cut-offs points for proteins predicting
MCI to AD
Individual protein cut-off values were derived for the
10 proteins identified by feature selection in the MCI
conversion model. Values predictive of conversion to AD
were; ApoC3, 105.5 mg/ml, TTR , 222 mg/ml, A1AT,
9.5 mg/ml, PEDF . 10.7 mg/ml, CC4 . 78.5 mg/ml,Fig. 2. Receiver operating characteristic (ROC) curves obtained for the test set fo
APOE only) from the full mild cognitive impairment, converter and nonconverter (
only, proteins 1 APOE 1 magnetic resonance imaging [MRI], and MRI only) inICAM-1, 99.72 ng/ml, RANTES, 33.8 ng/ml, A1AcidG
. 768.3 mg/ml, Cystatin C , 3.21 mg/ml, Clusterin . 402
mg/ml. Logistic regression was applied to test the 10 protein
cut-off concentrations and APOE genotype, the overall
model accuracy was 94.9%, with a sensitivity 73.6% and
specificity of 94.9% when using the full data set.4. Discussion
Previous studies by our group using data-driven pan-pro-
teomic approaches have identified a number of proteins as
diagnostic [1] progression [7,20] and markers of disease
severity [18]. The advent of high throughput multiplex plat-
forms facilitates the replication of such findings and raises
the potential of high throughput multiplexed markers for
use in clinical practice and in clinical trials [21–23]. In
this study we have used a multiplex antibody capture
platform to determine if our putative biomarkers are
associated with early disease stages and might have value
as prognostic markers. Using MRI as a surrogate of
disease pathology we identified a number of proteins that
were associated with atrophy either early in the disease
process (MCI) or in established dementia.
This approach of using MRI as a proxy for in vivo pa-
thology has previously been shown to be useful in
biomarker discovery, including in our study identifying
Clusterin as a putative marker of disease [7]. In this study
we identified RANTES, NSE, and transthyretin, in addi-
tion to Clusterin, to be associated with cortical atrophy
in the MCI group, with Clusterin showing the strongest
correlation with all brain regions assessed. The other pro-
teins have previously been implicated in AD. RANTES,
also known as chemokine ligand 5, is a protein known
to have an active role in recruiting leukocytes into in-
flammatory sites. We find a negative association betweenr (A) three models (proteins only, proteins1 apolipoprotein E [APOE], and
MCIc and MCInc) data sets and (B) for the test set for three models (proteins
the subset with protein plus MRI imaging data.
Table 4
Characteristics of the ROC curve for (A) the full data set without MRI and (B) ROC curve characteristics for the subset with MRI imaging data
(A) ROC characteristics without MRI
Classification model Sensitivity cut-off % SN % SP % PPV % NPV % ACC % ROC (AUC)
Protein 1 APOE 30 30.8 92.9 57.1 81.3 87.2 0.84
Protein only 30 30.8 92.9 57.1 81.3 87.2 0.78
Protein 1 APOE 50 53.9 88.1 58.3 86.1 80.0 0.84
Protein only 50 43.8 84.6 53.9 78.6 72.7 0.78
Protein 1 APOE 85 84.6 88.1 68.8 94.9 87.2 0.84
Protein only 85 84.6 71.4 47.8 93.8 74.5 0.78
(B) ROC characteristics with MRI
Classification model Sensitivity cut-off % SN % SP % PPV % NPV % ACC % ROC (AUC)
Protein 1 APOE 1 MRI 30 33.3 96.7 66.7 87.9 86.1 0.75
Protein only 30 33.3 93.3 50.0 87.5 83.3 0.82
MRI only 30 33.3 80.0 25.0 85.7 72.2 0.54
Protein 1 APOE 1 MRI 50 50.0 90.0 50.0 90.0 83.3 0.75
Protein only 50 50.0 86.7 42.9 89.7 80.6 0.82
MRI only 50 50.0 63.3 21.3 86.4 61.1 0.54
Protein 1 APOE 1 MRI 85 83.3 60.0 29.4 94.7 63.9 0.75
Protein only 85 83.3 66.7 33.3 95.2 69.4 0.82
MRI only 85 83.3 13.3 16.1 80.0 25.0 0.54
Abbreviations: ROC, receiver operating characteristic; MRI, magnetic resonance imaging; SN, sensitivity; SP, specificity; PPV, positive predictive value;
NPV, negative predictive value; ACC, accuracy; AUC, ROC area under curve for the protein and APOE classifiers.
NOTE. Three different sensitivity cut-off points were investigated.
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level with increased disease related pathology; the oppo-
site to previous reports in neurodegeneration [24–26].
One possible explanation might be that because we
observe RANTES association with atrophy only in
MCI and not in AD, perhaps a decrease early in disease
process is followed by an increase. Similar findings have
been previously reported for other proteins [27] and we
also observe a similar relationship with NSE, the second
protein we observe in association with brain atrophy.
This protein is thought to be an indicator of acute neuronal
damage [28,29] and has been associated with AD in some
but not all previous studies [30,31]. We find a positive
association between NSE and volume of hippocampus
and whole brain in MCI subjects, but in the AD group
we find a positive association instead with ventricular
volume. This inverse relationship with atrophy in
predisease and then positive correlation with atrophy in
disease suggests to us, that like RANTES, NSE might
be decreased in early disease stages (i.e. MCI) with a
rebound elevation in established AD.
In established AD we observe a different set of proteins
associated with disease severity as measured by atrophy
on MRI, in line with this concept of disease phase specific
biomarkers. A number of these belong to the group of apo-
lipoproteins (ApoE, ApoC3, and ApoA1). We found these
proteins were negatively associated with hippocampal, en-
torhinal cortical, and whole-brain volumes. The roles of
apolipoproteins in neurodegenerative disorders have been
studied extensively because the discovery that APOEwas a major susceptibility gene for AD [32,33]. In the
peripheral system, ApoE serves in the transport of
triglycerides, phospholipids, and cholesterol into cells
[34]. The literature on ApoE is conflicting with some
groups reporting lower ApoE in AD [35,36], with others
showing increased levels [37,38]. ApoE plasma
measurements derived from this study have been recently
published and are in agreement with the findings from the
North American Alzheimer’s Disease Neuroimaging
Initiative (ADNI), which reports an APOE genotype
effect [39].
Our present findings suggest that we have identified a
panel of plasma biomarkers, associated with neuroimaging
measures of disease, which may serve as readily accessible
markers of early disease severity. Moreover, we identify a
set of 10 protein biomarkers that can prospectively predict
disease conversion from MCI to AD within a year of blood
sampling. These results are supported by other evidence
that plasma proteins can have a role in early disease detec-
tion, with inflammatory proteins in particular being identi-
fied as possible predictors of conversion from MCI
[23,40]. It is important to note that when attempting to
compare such biomarker studies, the lack of standardized
reagents, particularly antibodies may result in different
outcomes reflecting technical differences between
analytical platforms more than disease biology. Therefore
our ability to replicate these proteins using an orthogonal
approach (mass spectrometry in discovery, multiplexed
immune capture in replication) makes these findings
particularly powerful and robust. Moreover, combining
A. Hye et al. / Alzheimer’s & Dementia 10 (2014) 799-807806MRI with protein measures did not improve predictive
power in contrast to previous studies where CSF marker
performance was improved in combination with MRI [41].
Although this study is built on findings from previous
discovery-led and replicated findings, further replication
will be needed. Ideally such replication should be in large,
longitudinal, population-based cohorts. Such a study would
be able to address potential confounds of the data reported
in this study including site-specific effects and representa-
tiveness of the cohorts. Further studies will also be needed
to address specificity. The markers we have identified are
often altered in other disease areas–inflammation, cardio-
vascular, respiratory, dental, and others–and it will be
important to distinguish the relative overlap and confound-
ing by these diseases. However, although the protein partic-
ipants in the panel we have identified are often altered in
other disease states, these diseases are all different and
therefore the panel itself may show specificity even if the
participants do not. This remains to be determined. It
also remains to be seen whether the panel we have identi-
fied is specific to AD or shows biomarker utility in relation
to other dementia syndromes. Although we used an assess-
ment protocol that we have previously shown is highly ac-
curate in distinguishing AD from other dementias based on
post-mortem confirmation, it will be interesting in due
course to correlate the behavior of our panel to specific
markers of dementia pathology such as biochemical or im-
aging measures of Ab and tau.
In summary, using a multiplexing approach we have vali-
dated a plasma protein panel as a marker reflecting disease
severity and for predicting disease progression within three
large multicenter cohorts. Such a marker set may have
considerable value in triaging patients with early memory
disorders, to other more invasive approaches such as molec-
ular markers in CSF and PET imaging, in clinical trials and
possibly in clinical practice.Acknowledgments
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1. Systematic review: We searched PubMed up to
February 2014 using the keywords, Alzheimer’s dis-
ease (AD), plasma, prediction, pathology, mild
cognitive impairment, and MCI to AD conversion.
2. Interpretation: This is the largest (n 5 1148) multi-
center plasma validation study based on previous dis-
covery candidate biomarkers. In addition, we
identified markers that are strongly associated with
disease endophenotype measures based on magnetic
resonance imaging and clinical severity. Moreover,
these biomarkers can prospectively predict disease
conversion from MCI to AD with an accuracy of
87% exceeding that of any previous reported plasma
biomarkers. Our findings suggest the potential role of
these biomarkers detected in plasma as indirect indi-
cators of AD pathology, and their utility as predictors
for future disease conversion.
3. Future directions: To validate the clinical utility of
the current study results, an independent study is
required of an equal or greater size to test the accu-
racy of this panel of biomarkers.References
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Table S1
Overview of proteins investigated in the current study
Protein name Method Study design Reported findings References
A2M 2-DGE; LC-MS/MS AD vs. control [ AD Hye et al. 2006
SAP 2-DGE; LC-MS/MS AD vs. control [ AD Hye et al. 2006
CFH 2-DGE; LC-MS/MS AD vs. control [ AD Hye et al. 2006, Cutler et al. 2008
Complement C4 2-DGE; LC-MS/MS AD vs. control Y AD Hye et al. 2006
ApoE 2-DGE; LC-MS/MS
and ELISA
PiB PET association [ Ab brain region Thambisetty et al. 2010
Clusterin 2-DGE; LC-MS/MS
and ELISA
Low vs. high brain
atrophy
[ High atrophy Thambisetty et al. 2011
ApoA1 2-DGE; LC-MS/MS SCD vs. FCD [ FCD Thambisetty et al. 2011
TTR 2-DGE; LC-MS/MS
and ELISA
SCD vs. FCD Y FCD Velayudhan et al. 2012
Ceruloplasmin 2-DGE; LC-MS/MS AD vs. control Y AD Hye et al. 2006
Ab 40 (Ab40) ELISA AD vs. control [ AD Mehta et al. 2001, Mayeux
et al, 2003
Ab 42 ELISA AD vs. control Y AD Hampel et al, 2010, Blennow
et al, 2001
A-1-acid glycoprotein ELISA AD vs. control Y AD Roher et al, 2010
Alpha1 antitrypsin
(A1AT)
ELISA AD vs. control [ AD Nielsen et al, 2007, Sun et al, 2003
Apo C3 Luminex E4 carrier vs. noncarrier Y AD Song et al, 2012
BDNF ELISA MRI association [ Age related white
atrophy
Driscoll et al, 2011
ELISA AD vs. control Y AD Aisa et al, 2010
ELISA AD vs. control Y AD Laske et, 2006
Beta-2-microglobulin Luminex [ AD Wilson et al, 2012
Cathepsin D Western blot AD vs. control Y AD Urbanelli et al, 2008
CRP Nephelometric detection SCD vs. FCD [ FCD Locascio et al, 2008
Cystatin C Immunoturbidimetric
assay
AD vs. control Y AD Zhong et al, 2013;
ELISA AD vs. control No change Sundel€of et al, 2010
ICAM-1 IHC AD vs. control [ AD Frohman et al, 1991
NCAM ELISA AD vs. control Y AD Aisa et al, 2010
NSE Electrochemiluminescence
assay
AD vs. control No change Chaves et al, 2010;
Immunoradiometric assay AD vs. control [ AD Blennow et al, 1994
PAI-1 ELISA AD vs. control [ AD Sutton et al, 1994; Akenami et al, 1997
PEDF 2-DGE; LC-MS/MS AD vs. control [ AD Castano et al, 2006
RANTES Q-RT-PCR AD vs. control [ AD Kester et al, 2011
[ AD Tripathy et al, 2011; Reynolds et al, 2007
VCAM-1 ELISA AD vs. control [ AD Zuliani et al, 2008
sRAGE ELISA AD vs. control YAD Emanuele et al. 2005
ELISA AD vs. MCI YMCI Chidoni et al. 2008
Abbreviations: A2M, alpha-2-macroglobulin; 2-DGE, two-dimensional gel electrophoresis; LC-MS/MS, liquid chromatography tandemmass spectrometry;
SAP, serum amyloid P; CFH, complement factor H; ELISA, enzyme-linked immunosorbent assay; TTR, transthyretin; Ab, amyloid beta; CRP, C-reactive pro-
tein; IHC, immunohistochemistry; NSE, neuron-specific enolase; Q-RT-PCR, quantitative reverse transcription polymerase chain reaction; MCI, mild cognitive
impairment; PiB, Pittsburgh compound B; SCD, Slow cognitive decline; FCD, Fast cognitive decline.
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S2: Milliplex MAP assays
Seven Milliplex MAP multiplex panels (96-well plate
format; EMD Millipore) were utilized: human neurodegen-
erative panel 1 (7-plex) cat.# HNDG1MAG-36K, panel 2
(6-plex) cat.# HNDG2MAG-36K, panel 3 (10-plex) HNDG3-
36K, panel 4 (5-plex) HNDG4-36K, human kidney toxicity
panel 2 (3-plex) cat.# HKTX2MAG-38K, human neurolog-
ical disorders magnetic panel 1 (7-plex) cat.# HND1MAG-
39K, and panel 2 (4-plex) cat.# HND2MAG-39K.
S3: Immunoassay protocol
The Luminex xMAP technology (Austin, TX) uses a
solid phase approach to analyze multiple proteins. In brief,
the xMAP technology is a flow cytometric-based platform
that uses microspheres inserted with a ratio of two different
fluorescent dyes. In theory, up to 100 differently colored
beads can be generated with a theoretical multiplex capacity
of up to 100 assays per well of a 96-well plate. The capture
antibody is covalently coupled to the bead, and immunoas-
says are run under standard sandwich immunoassay formats.
The plasma samples were first diluted as recommended in
the protocol for each Milliplex MAP assay. Each assay well
was first rinsed with 100 mL wash buffer (1! L-WB) before
sample loading. Twenty-five microliters of assay buffer was
added to either 25 mL controls or samples followed by 25 mL
of beads to bring the total volume in each well to 75 mL. The
assay plates were incubated for 2 h at room temperature or
overnight with agitation on an orbital shaker. The beads in
the plate were washed three times with 100 mL wash buffer
and incubated for 1 h with 25 mL of biotinylated detection
antibody. Twenty-five microliters of fluorescently labeled
reporter (streptavidin-PE) molecule was added to the detec-
tion antibody for a further 30min. Finally the assay platewas
washed three times with 100 mL of wash buffer and the beads
suspended in 100 mL of sheath fluid. All plasma samples
were assayed in duplicate and a pooled plasma (Mastermix)
sample was included as a positive control in addition to high
and low QC per plate.
S4: Data quality checks (QC) and preprocessing
Fluorescence in each well was measured using Luminex
200 (Austin, TX) instrument and the results were analyzed
with the Xponent 3.1 (Luminex) software. Median fluores-
cent intensity (MFI) values were exported and the character-
istics of the individual samples were confirmed by
calculating the mean, standard deviation, and coefficient of
variation (CV) % from the MFI readouts. All processed
data points were then imported into Sigma Plot (Systat,
ver. 12). Using a five-parameter logistic curve fitting method
the concentrations of the unknown plasma samples and the
master mix were calculated.
Any individual samples that recorded a CV.15% for
either duplicate was eliminated; if both duplicates were
out of range then both data points were excluded.
Individual analytes were then assessed for quality by
applying rank according to their performance in the assay
(31 plates; 1153 plasma samples) and defined using a scoring
system based on four criteria as follows:
Criteria 1. Standard curve rank: 15 Good quality-within
linear section on standard curve and within QC range.
2 5 Moderate quality, spread across the linear section on
standard curve, clustered either higher or lower than QC.
3 5 Poor quality, not on linear section at all, below low
QC or higher than top QC.
Criteria 2. Intra-assay CV (%) for QC1 and QC2,
CV,30% accepted (point for each QC value).
Criteria 3. Interassay CV (%) for our in-house pooled
sample (master mix), CV,30% accepted.
Criteria 4. Missing data defined as samples that could not
be reliably intrapolated from the standard curve. (1) MFI
values outside the quantifiable range. (2) Technical failure
resulting in no MFI value being generated.
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